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Case-fatality rates in Ebola treatment centers (ETCs) var-
ied widely during the Ebola virus disease (EVD) outbreak 
in West Africa. We assessed the influence of referral path-
way on ETC case-fatality rates with a retrospective cohort 
of 126 patients treated at the Mathaska ETC in Port Loko, 
Sierra Leone. The patients consisted of persons who had 
confirmed EVD when transferred to the ETC or who had 
been diagnosed onsite. The case-fatality rate for trans-
ferred patients was 46% versus 67% for patients diag-
nosed onsite (p = 0.02). The difference was mediated by 
Ebola viral load at diagnosis, suggesting a survival selec-
tion bias. Comparisons of case-fatality rates across ETCs 
and clinical management strategies should account for po-
tential survival selection bias.
As of February 14, 2016, the 2014–2016 outbreak of Ebola virus in West Africa had resulted in >14,000 
cases of Ebola virus disease (EVD) and ≈4,000 deaths in 
Sierra Leone (1). The country’s strategy for managing the 
outbreak and isolating patients included decentralized Eb-
ola treatment centers (ETCs) and Ebola isolation centers 
(EICs), which were also known as community care centers 
and holding centers (2,3). EICs were transitional facilities 
meant for admission and isolation of patients who were 
awaiting results of Ebola diagnostic testing (real-time 
PCR) and provision of basic care (e.g., administration of 
oral rehydration solution) (2). EIC patients with Ebola vi-
rus–negative test results were discharged, and those with 
positive results were transferred to an ETC. In contrast 
to EICs, ETCs could care for patients suspected of hav-
ing and those confirmed to have EVD without transfer of 
patients between facilities. EICs were initially designed 
to address a shortfall in ETC bed capacity, although their 
use continued even as ETC bed capacity increased during 
the outbreak (1).
Recent studies on EVD clinical outcomes (2,4–7) 
demonstrate considerable variability in case-fatality rates 
(37%–74%) and call for further analyses to understand the 
reason(s) for this variability. Predictors of higher case-fa-
tality rate after ETC admission are age (4–6,8) and higher 
viremia at diagnosis (9,10) and, less consistently, longer 
symptom duration before admission (4–6,8,9); clinical 
presentation with confusion, diarrhea, and conjunctivitis 
(4–6,8); and biochemical evidence of kidney injury, hepa-
titis, or both (5). One study reported early EVD-associated 
deaths (i.e., in the community) with a case-fatality rate of 
24% before ETC transfer (9). None of these studies ex-
amined the care pathway of EVD patients or the extent to 
which direct admission to an ETC versus transfer from an 
EIC influenced case-fatality rates measured in ETCs.
We sought to investigate whether referral pathway had 
any influence on case-fatality rate. We specifically sought 
to determine whether there was a statistically significant 
difference in case-fatality rate between EVD patients ad-
mitted directly to the ETC compared with patients first ad-
mitted to an EIC and subsequently transferred to the ETC 
after confirmation of EVD status.
Methods
Study Setting
We conducted a retrospective cohort study on all patients 
with EVD admitted to the Mathaska ETC in Port Loko 
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district, Sierra Leone, during December 12, 2014–March 
14, 2015 (i.e., from the time the ETC opened until the first 
author of this article left Sierra Leone). GOAL Global 
(https://www.goalglobal.org/) ran the ETC with national 
and international staff, and the ETC received patients from 
Port Loko and the neighboring district, Kambia. The ETC 
received patients via 2 referral paths: 1) patients transferred 
from an EICs after testing positive for Ebola virus (cohort 
1, confirmed cases); and 2) patients admitted after meeting 
the Sierra Leone Ministry of Health and Sanitation (MoHS) 
case definition of presumed EVD detected through active 
monitoring of contacts in quarantine or through passive 
surveillance in communities and non-EVD healthcare facil-
ities (cohort 2, suspected or probable cases). We included 
cohort 2 patients in the study only if they were confirmed to 
have EVD (i.e., Ebola-positive real-time PCR results) after 
admission to the ETC.
All cases of EVD during the study period in Port Loko 
and Kambia were confirmed by PCR testing of blood; 
testing was performed at the Public Health England refer-
ence laboratory in Port Loko. Patients received symptom-
atic treatment according to World Health Organization and 
MoHS guidelines (11). The Sierra Leone Ethics and Scien-
tific Review Committee approved the study.
Data and Analyses
We used EpiData version 3.1 software (EpiData Associa-
tion, Odense, Denmark) to extract and compare the fol-
lowing data for directly admitted and transferred patients: 
demographic data (age, sex); clinical data (time from 
symptom onset to EVD test, death vs. survival in ETC); 
laboratory data (PCR results, cycle threshold [Ct]); and re-
ferral and admission data from clinical charts. For all pa-
tients, we used the Ct from the initial positive blood sample 
(i.e., for cohort 1, the blood sample was from the EIC). 
The Ct is inversely proportional to the level of virus in the 
blood sample (12). We verified clinical documentation of 
referral source and cohort 1 classification from MoHS sur-
veillance data and by checking the EVD test date against 
the ETC admission date. While waiting for PCR results, 6 
EIC patients were admitted to the ETC’s ward for patients 
with suspected or probable EVD. To be consistent in our 
analysis, we considered those patients directly admitted 
patients (cohort 1).
We calculated the time from symptom onset to EVD 
test by subtracting the self-reported symptoms-onset date 
from the first EVD test (which occurred on the date of ad-
mission to an EIC or ETC). We assessed the number of 
symptoms at admission as well as the stage of disease (i.e., 
the presence of mild influenza-like symptoms, wet symp-
toms [i.e., diarrhea or vomiting, or both], or hemorrhagic 
symptoms). Case-fatality was recorded as a death in the 
ETC. Survival among patients with confirmed EVD was 
defined as a resolution of viremia, as confirmed by an Eb-
ola virus–negative PCR result. We assessed for differences 
in proportions by using the χ2 test for categorical variables 
with >5 observations/cell in a frequency table (death by 
cohort, admission stage by cohort, case-fatality rate by co-
hort). We used the t-test to compare continuous variables if 
normally distributed (age distribution between cohorts); we 
applied the Wilcoxon–Mann–Whitney rank test if nonnor-
mal distribution was found (interval from symptom onset to 
EVD testing between cohorts, interval from symptom onset 
to ETC admission between cohorts, Ct between cohorts, as-
sociation between low Ct and increased case-fatality rate). 
To graphically represent the time to death, we used Kaplan-
Meier survival curves. To assess difference in fatality rates 
between transferred and directly admitted patients, we used 
Cox proportional hazards analysis adjusted for Ct value; 
no significant deviations from the proportional hazards as-
sumption were found. We used Stata 12 (StataCorp LLC, 
College Station, TX, USA) to analyze data.
Results
During the study period, 227 patients were transferred and 
admitted to the ETC; 128 of these patients had EVD. Of 
those 128 patients, 126 were included in the study. The 2 
excluded EVD patients were transferred to another ETC, 
and their outcomes were unknown. Female patients com-
prised 53% of the patients. The median age of patients was 
30 years (interquartile range [IQR] 18–42); 27 patients 
were <15 years of age.
The overall EVD case-fatality rate at Mathaska ETC 
was 59% (74/126 patients). The case-fatality rate was high-
est among children <2 years of age (67%) and persons >35 
years of age (78%). Of the 74 patients who died, 72 (97%) 
died within 9 days of ETC admission (Figure).
Cohort 1 comprised 48 patients who were transferred 
to Mathaska ETC from EICs (n = 45) or other local ETCs 
(n = 3) with a confirmed EVD diagnosis. Cohort 2 com-
prised 78 patients: 16 from quarantine, 1 from a non-EVD 
hospital, 6 from EICs in Kambia district, 1 from another 
ETC, and 53 who were referred through community sur-
veillance. The referral pathway was missing for 1 patient. 
The age distribution was similar between cohorts (p = 0.2) 
(Table). The time from symptom onset to admission at the 
ETC was shorter for cohort 2 patients than cohort 1 pa-
tients (4 vs. 6 days; p<0.001), and the Ct at diagnosis was 
higher among cohort 1 patients than cohort 2 patients (23 
vs. 20; p<0.001).
The median duration of symptoms before EVD test-
ing was similar between cohorts 1 and 2 (median 4 [IQR 
2–5] days vs. 4 [IQR 3–6] days; p = 0.7) (Table). A low-
er Ct was associated with an increased case-fatality rate 
(p<0.001). Neither the quantity of symptoms (mean 6.5 
[cohort 1] vs. 6.2 [cohort 2]; p = 0.3) nor the distribution of 
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patients according to severity stages differed significantly 
between cohorts 1 and 2 (p = 0.8).
The case-fatality rate was lower for cohort 1 (EVD 
confirmed before transfer) than cohort 2 (46% vs. 67%; p 
= 0.02) (Table). After we adjusted for Ct at diagnosis, the 
case-fatality rate was no longer significantly different be-
tween cohorts 1 and 2 (p = 0.2).
Discussion
Understanding sources of variability in observed case-fa-
tality rates during the 2014–2016 Ebola virus outbreak in 
West Africa is essential for interpreting case-fatality rate as 
part of routine monitoring of a clinical program (1) and for 
evaluating the effect of clinical interventions. We investi-
gated whether patients transferred to Mathaska ETC had a 
lower case-fatality rate than patients directly admitted to 
the ETC, and our results show that referral pathway does 
influence the case-fatality rate. This finding confirms the 
observations from previous studies showing that virus load 
and patient age are associated with EVD case fatality (4).
In Sierra Leone, 5 ETCs with different referral path-
ways reported different case-fatality rates. Among EVD 
patients admitted and diagnosed onsite at Kenema Gov-
ernment Hospital early in the outbreak, the case-fatality 
rate was 74% (64 deaths/87 patients) (6). The Médecins 
Sans Frontières ETC in Kailahun admitted and diagnosed 
patients on-site and reported a case-fatality rate of 51% 
(270 deaths/525 patients) (4). In Bo, the case-fatality rate 
was 66% (142/216) among all confirmed EVD patients 
detected in the community during the study period, but it 
was 40% (49/123) among the detected EVD patients who 
survived until admittance to an ETC (9). In contrast, the 
Save the Children ETC in Kerry Town, Sierra Leone, had a 
case-fatality rate of 37% (55 deaths/150 patients) and was 
equipped to provide a higher level of care (additional di-
agnostics) but received only confirmed patients from EICs 
(5). Among the 85 EVD patients admitted to the EIC in the 
Jui Government Hospital in Sierra Leone, the case-fatality 
rate was 60%, although it was unclear whether the deaths 
occurred in the EIC or in the ETC to which confirmed pa-
tients were transferred (7).
We found that the influence of referral pathways on the 
estimated case-fatality rate at Mathaska ETC was probably 
mediated by differences in virus load at diagnosis. This 
finding supports the hypothesis that differences in observed 
case-fatality rates by referral pathway are probably due to 
survival selection bias rather than differences in patient 
care at individual ETCs. We did not measure case-fatality 
rates in the EICs. Thus, we cannot infer the role of EIC ver-
sus ETC on case-fatality rate before EVD confirmation and 
transfer to EVD-confirmed wards. Furthermore, although 
the difference in virus load among the 2 cohorts suggests 
that the transferred patients were in recovery, there was no 
difference in the number of symptoms nor in the severity 
of disease when patients were admitted to the ETC. We 
did not, however, assess the degree of the individual symp-
toms, and that information might have added clarity.
Our data, along with the case-fatality rates reported for 
other ETCs in Sierra Leone (4,5), suggest that if the referral 
pathway (i.e., time spent in EICs) is long, patients may die 
before getting tested for EVD disease. Thus, EVD patients 
transferred to the ETC represent a different patient popula-
tion than those diagnosed on-site. Our findings of possible 
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Figure. Kaplan-Meier survival plot stratified by referral pathway 
for patients admitted directly to an Ebola treatment center (ETC) 
with confirmed Ebola virus disease (cohort 1, blue line) and for 
patients diagnosed at the ETC (cohort 2, red line). Plots show 
the percentage of patients surviving as a function of time (days) 





Table. Demographic and epidemiologic differences between 2 patient cohorts in a study of the sources of variability in case-fatality 
rates in Ebola treatment centers, Sierra Leone, 2014–2016* 
Variable Cohort 1, n = 48 Cohort 2, n = 78 p value 
Case-fatality rate, % 46 67 0.02 
Age, median, IQR 29 (14–40) 34 (20–45) 0.2 
Children <15 years of age, no. (%) 12 (44) 15 (56) 0.4 
Days from symptom onset to EVD testing (IQR) 4 (2–5) 4 (3–6) 0.7 
Days from symptom onset to admission at ETC, median (IQR) 6 (4–7) 4 (2–5) <0.001 
Ct, median (IQR)† 23 (21–26) 20 (18–23) <0.001 
*Cohort 1 consisted of patients admitted directly to the ETC (Ebola treatment center) with confirmed EVD (Ebola virus disease); cohort 2 consisted of 
patients admitted directly to the ETC, where they were subsequently diagnosed with EVD. Ct, cycle threshold; IQR, interquartile range. 
†Obtained from first blood sample drawn. 
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survivor selection bias are consistent with findings in previ-
ous reports showing a higher case-fatality rate among pa-
tients who were admitted early after symptom onset (4,5), 
an initially counter-intuitive finding, given the provision 
early supportive management. In Kailahun, patients who 
traveled long distances to reach the ETC had a lower case-
fatality rate than those who traveled shorter distances (4). 
Although, as pointed out by Hunt et al. (5), reported symp-
tom onset date is subject to recall bias. Thus studies of clin-
ical predictors and comparisons of case-fatality rates across 
ETCs must account for potential survivor selection bias. 
Symptom-onset date is prone to recall and social desirabil-
ity bias, but referral pathways are an objective indicator 
of potential differences in patient populations admitted to 
ETCs. From a clinical perspective in the ETC, measuring 
and making decisions based on anticipated efficacy of sup-
portive management or experimental drugs must account 
for these differences in patients. A key social mobilization 
message during the West Africa outbreak was the impor-
tance of early diagnosis and treatment to save lives (not just 
prevent transmission), drawing on experience and evidence 
from other infectious diseases with similar end-organ ef-
fects. Invasive monitoring and careful fluid management 
probably contributed to the low case-fatality rates observed 
in the study in Kerry Town, but as the authors noted, the 
study population was subject to selection bias (5), which 
limits the generalizability of care-associated predictors of 
outcome. Rigorous study of all patients with confirmed 
EVD and estimates of case-fatality rate at each point in the 
referral pathway (community, EIC, ETC) are needed to dis-
entangle survival selection bias from the effect of early care 
and care-associated predictors of case-fatality rate.
In conclusion, case-fatality rates across ETCs may de-
pend on which patients are referred to the facilities and, 
thus, the distribution of known predictors, such as age and 
virus load. Referral pathways and the potential for survival 
selection bias should be accounted for when comparing 
case-fatality rates between studies, ETCs, and interventions 
and when planning and evaluating future clinical trials.
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